**Baxdrostat phase 3 BaxHTN achieves 9-10 mmHg SBP drop in resistant hypertension**
Key Questions
What were the results of the BaxHTN phase 3 trial?
Baxdrostat achieved 9-10 mmHg SBP reduction on top of existing resistant hypertension medications. This positions it as a potential guideline addition.
How does BP reduction with baxdrostat impact CV risk?
Each 5 mmHg SBP reduction links to 10% CV risk drop, even in CKD. Baxdrostat's effects build on this in resistant cases.
What is the context of pulse pressure in resistant hypertension?
Pulse pressure associates with severity and worse outcomes. Baxdrostat addresses this in uncontrolled hypertension atop standard Rx.
BaxHTN ph3: 9-10 mmHg SBP atop Rx resistant HTN. Guideline potential; watch CVOT; pulse pressure severity context.
Sources (2)
Updated May 6, 2026